Pamidronate disodium and Hepatitis fulminant - a phase IV clinical study of FDA data

Summary:

Hepatitis fulminant is reported only by a few people who take Pamidronate Disodium.

The phase IV clinical study analyzes which people take Pamidronate disodium and have Hepatitis fulminant. It is created by eHealthMe based on reports of 4,924 people who have side effects while taking Pamidronate disodium from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 30, 2023

4,924 people reported to have side effects when taking Pamidronate disodium.
Among them, 4 people (0.08%) have Hepatitis fulminant.

What is Pamidronate disodium?

Pamidronate disodium has active ingredients of pamidronate disodium. eHealthMe is studying from 4,940 Pamidronate disodium users for its effectiveness, alternative drugs and more.

What is Hepatitis fulminant?

Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function) is found to be associated with 966 drugs and 650 conditions by eHealthMe.

Number of Pamidronate disodium and Hepatitis fulminant reports submitted per year:

Could Pamidronate disodium cause Hepatitis fulminant?

Time on Pamidronate disodium when people have Hepatitis fulminant *:

Gender of people who have Hepatitis fulminant when taking Pamidronate disodium *:

female: 100 %
male: 0.0 %

Age of people who have Hepatitis fulminant when taking Pamidronate disodium *:

Common drugs people take besides Pamidronate disodium *:

Aromasin: 4 people, 100.00%
Fluconazole: 3 people, 75.00%

Common side effects people have besides Hepatitis fulminant *:

Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 4 people, 100.00%
Gallstones (stone formation by bile component): 4 people, 100.00%
Blood Test Abnormal: 4 people, 100.00%
Multi-Organ Failure (multisystem organ failure): 3 people, 75.00%
Metastases To Bone (cancer spreads to bone): 3 people, 75.00%
Diarrhea: 3 people, 75.00%
Bone Pain: 3 people, 75.00%
Drug Ineffective: 2 people, 50.00%
Asterixis (flapping tremor, or liver flap): 2 people, 50.00%
Skin Discoloration - Bluish (bluish colour of skin): 1 person, 25.00%

Common conditions people have *:

Metastases To Bone (cancer spreads to bone): 4 people, 100.00%
Breast Cancer Female: 4 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Pamidronate disodium and have Hepatitis fulminant?

Check whether Hepatitis fulminant is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .

Related studies

Common Pamidronate disodium side effects:

Browse all side effects of Pamidronate disodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Hepatitis fulminant treatments and more:

Hepatitis fulminant (4,522 reports)

COVID vaccines that are related to Hepatitis fulminant:

Common drugs associated with Hepatitis fulminant:

All the drugs that are associated with Hepatitis fulminant:

Hepatitis fulminant (966 drugs)

Common conditions associated with Hepatitis fulminant:

High blood pressure: 227 reports
Hiv infection: 180 reports
Pain: 121 reports
Rheumatoid arthritis: 108 reports

All the conditions that are associated with Hepatitis fulminant:

Hepatitis fulminant (650 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pamidronate disodium (the active ingredients of Pamidronate disodium) and Pamidronate disodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.